- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02483182
Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores
A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint of this study are:
- "Time to healing" - Clinician-assessed duration in days of herpes labialis episode.
- Patient-assessed duration and intensity of pain by Visual Analog Scale (VAS).
- Safety and tolerability following five consecutive treatment days with five times daily topical administration.
The secondary endpoints of this study are:
- Proportion of subjects with non - ulcerative herpes lesion.
- Time for herpes labialis recurrences
Subject safety will be assessed following treatment by ZEP-3 ointment 1.0% or acyclovir cream 5% treatment, using measurements of the following variables:
- Physical examination,
- Vital Signs (HR, BP, Body temperature),
- Adverse events recording and
- Concomitant medications
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Netanya, Israel
- Dermatology out-patients clinic, Lev Hayasmin MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Prior to enrollment in this study, candidates must meet ALL of the following inclusion criteria:
- Patients suffering from recurrent Herpes labialis with history of at least 3 cold sores recurrences during the previous 12 months.
- Participants, either male or female are between 18 and 75 years of age.
Patients arrive at the clinic with any symptom of an acute Herpes labialis episode.
Or, patients arrive at the clinic within 48 hours of treatment initiation for a recurrent Herpes labialis episode.
- Patients with previous Herpes labialis episode must be healed for at least 14 days before baseline visit
- Patients with no history of reaction to topical products.
- Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study.
- Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol.
- Patient is willing and able to provide written informed consent prior to any study procedure.
Exclusion Criteria:
- Subject has abnormal skin conditions or significant facial hair at or near the investigational area
- Subject has any body piercing in or around the area ordinarily affected by cold sores.
- Subjects with a history of cardiac abnormalities.
- Subject has a recent history of renal dysfunction or serious hepatic disease
- Subject has an active malignancy or immunodeficient disease
- Subject who is unwilling to stop using topical medical, OTC, cosmetics or facial skin care products in or around the oral area during the study period.
- Subject requires chronic use of immunomodifying drugs or topical steroids on or near the face.
- Subject requires chronic use of anti-viral medication.
- Subject requires chronic use of analgesics, pain medication or non-steroidal anti inflammatory agents (NSAIDs).
- History of allergic or adverse response to acyclovir, or any related anti-viral drug.
- Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir.
- Subject has had a herpes vaccine.
- Females during pregnancy, lactation or breastfeeding.
- Subject has a history of alcoholism or drug abuse within the preceding 12 months.
- Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device.
- Any history which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
- Subjects with immune deficiency conditions including acquired immune deficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZEP-3 ointment 1.0%
Topical administration
|
|
Active Comparator: Acyclovir cream 5%
Topical administration
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinician-assessed "Time to healing"
Time Frame: Up to 14 days
|
Up to 14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time for Herpes labialis recurrences
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shemer Avner, Prof., M.D., Dermatology out-patients clinic, Lev Hayasmin - Medical center, Natanya, ISRAEL
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZEP - 002 - IL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Labialis
-
BayerActive, not recruitingRecurrent Herpes LabialisUnited States
-
Topical RemedyBenu BioPharma, LLCCompletedRecurrent Herpes LabialisUnited States
-
NanoBio CorporationCompletedRecurrent Herpes LabialisUnited States
-
Southern California University of Health SciencesCompletedHerpes SimplexUnited States
-
Leciel BonoRecruitingHSV-1 | Herpes Simplex Labialis | Virus | Herpes Simplex 1United States
-
Topical RemedyBenu BioPharma, LLC; Accelovance; Optimal ResearchCompletedRecurrent Herpes LabialisUnited States
-
University of ZurichDevirex AGCompleted
-
NovartisCompleted
-
Hadassah Medical OrganizationUnknownReccurent Herpes Labialis
-
Laboratoire Boreaderme Inc.Ecogene 21Unknown
Clinical Trials on ZEP-3 ointment 1.0%
-
Shulov Innovate for Science Ltd. 2012Completed
-
Technoderma Medicines Inc.Therapeutics, Inc.Not yet recruiting
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Galderma R&DCompleted
-
DFB Soria, LLCBioskin GmbH; US Biotest, Inc.CompletedPlaque PsoriasisUnited States
-
Assaf-Harofeh Medical CenterUnknownUremic Pruritus
-
HK inno.N CorporationNot yet recruiting
-
Emory UniversityGeorgia Center for Oncology Research & EducationNot yet recruitingHuman Immunodeficiency Virus | Human Papilloma Virus | Anal Intraepithelial Neoplasia | High-Grade Squamous Intraepithelial LesionsUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting